NWBO stock forecast, quote, news & analysis

Key Takeaways

• Northwest Biotherapeutics (NWBO) has traded in a narrow range near $0.17 over the past 30 days, with the 30-day percentage change roughly flat at well under 10%.
• The stock's 52-week range spans roughly $0.14 to $0.34, reflecting the speculative nature of a pre-commercial biotechnology company.
• The central value driver remains the UK Medicines and Healthcare products Regulatory Agency (MHRA) decision on the DCVax-L marketing authorization application for glioblastoma.
• Financing risk is a recurring theme: the company operates a "raise-as-you-go" model with a limited cash position and frequent dilutive raises.
• A single covering analyst (First Berlin Equity Research) maintains a Buy rating with a $1.00 price target.

Current Market Snapshot

Northwest Biotherapeutics trades on the OTCQB market under the symbol NWBO. As of mid-September 2026, the stock was changing hands around $0.17, having consolidated near that level for several weeks. Daily trading volumes have been volatile, with occasional spikes alongside financing announcements and clinical data releases, but the share price has shown limited directional conviction. With roughly 1.7 billion shares outstanding, the company carries a micro-cap valuation of approximately $270–290 million. Investor sentiment remains tightly linked to a single binary event: the outcome of the company's UK regulatory filing for its lead candidate.

Northwest Biotherapeutics (NWBO) Business Overview and Competitive Position

Founded in 1996 and headquartered in Bethesda, Maryland, Northwest Biotherapeutics is a clinical-stage biotechnology company developing DCVax, a personalized dendritic cell immunotherapy platform. The technology uses a patient's own activated dendritic cells to mobilize the immune system against solid-tumor cancers. The lead product candidate, DCVax-L, targets glioblastoma multiforme (GBM), one of the most aggressive and lethal brain cancers, and completed a 331-patient Phase 3 trial. A second candidate, DCVax-Direct, is designed for inoperable solid tumors and has completed an early-stage trial across more than a dozen cancer types.

The company's competitive position rests on a differentiated, personalized approach to oncology and a manufacturing footprint that includes a facility in Sawston, United Kingdom. However, NWBO remains pre-commercial, generates minimal revenue, and depends heavily on periodic equity-linked financings to fund operations — characteristics that distinguish it from larger, later-stage oncology peers and explain the stock's elevated volatility and low institutional ownership.

Recent Developments Driving NWBO

Several verified developments have shaped the investment narrative around NWBO in recent weeks:

• New statistical analyses of DCVax-L. At the 2026 British Neuro-Oncology Society (BNOS) meeting, the company presented independent propensity score matching and inverse probability weighting analyses of its Phase 3 data. These re-analyses estimated an overall survival benefit of 3.4–6.3 months versus the original 2.8-month result, with results remaining statistically significant across three external trial datasets.
• Financing activity. In late July 2026, the company entered a $4.9 million convertible promissory note with an affiliate of Yorkville Advisors, alongside a standby equity subscription agreement allowing up to $50 million of future share issuances at a discount to market.
• Financial results. The company reported full-year 2025 revenue of approximately $1.4 million and continued operating losses. First-quarter 2026 revenue was roughly $0.5 million, and the second quarter of 2026 produced a net loss of about $17.9 million.
• Analyst coverage. First Berlin Equity Research reiterated a Buy rating and a $1.00 twelve-month price target, citing the strengthened regulatory evidence package and manufacturing-readiness progress at the Sawston facility.
• Leadership additions. The company appointed Dr. Annalisa Jenkins as a Strategic Adviser in April 2026, strengthening commercial and regulatory execution capabilities ahead of a potential launch.

Trending AI Robots

For investors seeking a more systematic approach to market analysis, Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers across various asset classes, but only the top-performing and most relevant bots appear in this featured section. Each bot is built around a distinct strategy, timeframe, and set of performance metrics, allowing users to explore approaches ranging from short-term signal generation to longer-horizon trend tracking. The curated list provides a useful starting point for comparing different automated strategies and evaluating how AI-driven analysis complements conventional research. Browse the page to see which robots are currently leading in performance and relevance.

2026 Outlook and What Investors Should Watch

The dominant catalyst for NWBO in 2026 is the MHRA's decision on the DCVax-L marketing authorization application, which was originally submitted in 2023 and is now in the latter stages of review. A positive outcome would likely shift focus toward pricing and reimbursement negotiations with the National Institute for Health and Care Excellence (NICE) and a potential first commercial launch in the United Kingdom. Conversely, a delay or rejection would represent a meaningful setback for the investment thesis.

Beyond the regulatory decision, investors should monitor the company's cash runway and financing cadence. With a limited cash position and a raise-as-you-go model, further dilutive issuances are a realistic possibility that could pressure the share price. Other factors to watch include manufacturing scale-up at the Sawston facility, any progress toward additional regulatory filings in the United States, Canada, or Europe, and the trajectory of operating expenses as the company prepares for potential commercialization. Analyst expectations remain optimistic relative to the current share price, but the wide gap between the market price and the $1.00 target underscores the binary, event-driven nature of the stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations